CDSCO Current Affairs - 2020
The Japanese Government recently approved Dexamethasone as a second treatment of COVID-19. The approval came in after Britain showed that the drug reduced death rates in COVID-19 patients.
Dexamethasone has been approved for treatment along with Remdesivir. A clinical trial of UK proved that Dexamethasone as the first drug saved lives of COVID-19.
India had approved the use of Dexamethasone in June 2020. The Drug was found to reduce mortality by one-third of COVID-19 patients who are on ventilators and one-fifth of patients on oxygen therapy.
In India, the Health Ministry approved Dexamethasone as an alternative to Methylprednisolone.
So far, India has approved the following drugs to treat COVID-19
It was approved by the Central Drug Standard Control Organization (CDSCO) for both children and adult.
It is being used on patients with mild to moderate COVID-19 in India.
This drug was approved by the Drug Controller General of India.
The drug is expected to reduce the mortality of COVID-19 patients by 3.8%. Still India has approved the drug to treat COVID-19.
CDSCO and DGCI
Both operate under Ministry of Health and Family Welfare. However, the DGCI operates within CDSCO.
Tags: CDSCO • Central Drugs Standard Control Organisation (CDSCO) • DCGI • Dexamethasone • Itolizumab Injection
On May 20, 2020, the Sree Chitra Tirunal Institute for Medical Science and Technology operating under Department of Science and Technology has launched magnetic nano particle based RNA extraction kit called “Agappe Chitra Magna”.
The Agappe Chitra Magna kit was validated by the National Institute of Virology. The kit was developed by the SCTIMST and was transferred to Agappe Diagnostics and hence the name Agappe Chitra Magna kit.
The approval of the kit was provided by the Central Drugs Standard Control Organization (CDSCO).
About the kit
The kit uses an innovative technology of magnetic nano particles to isolate RNA. The nanoparticles are used to capture RNA from the sample of the patient. The kit enhanced detection of positive cases. This is because the magnetic nanoparticles binds to the viral RNA and when exposed to magnetic field gives concentrated RNA.
The kit is highly affordable. The price of the kit is Rs 300 and is expected to come down to Rs 150. This will help to address the needs of India. The Government of India has estimated that the country will need around 8 lakhs kits per month for the next six months. The Agappe Diagnostics has manufacturing capacity of 3 lakh kits per month.